Autologous Stem Cell and Non-Stem Cell Based Therapies Market covers the latest developments and growth opportunities. Trends, revenue analysis, Global industry share and dynamics are presented to optimize the business. The vital Track insights, opportunities in existing and emerging segments are explained. This report has published stating that the Global Market is anticipated to expand significantly at Million US$ in 2019 and is projected to reach Million US$ by 2023, at a CAGR of during the forecast period.

Get Sample Copy athttps://www.orianresearch.com/request-sample/1146196

In this report we cover the players as far as item fulfillment and business procedure they embrace to continue in Autologous Stem Cell and Non-Stem Cell Based Therapies market. This report analyses the aggressive scene regarding markets, applications, and geologies. The Competitive Strategic Window enables the seller to characterize an arrangement or fit between their capacities and open doors for future development prospects. During a forecast period, it characterizes the ideal or good fit for the merchants to embrace progressive merger and acquisitions procedures, topography extension, inquire about and advancement, new product acquaintance techniques with execute further business development.

The major players profiled in this report include:,U.S. STEM CELL, INC.,Brainstorm Cell Therapeutics,Cytori,Dendreon Corporation,Fibrocell,Lion Biotechnologies,Caladrius Biosciences,Opexa Therapeutics,Orgenesis,Regenexx,Genzyme,Antria,Regeneus,Mesoblast,Pluristem Therapeutics Inc,Tigenix,Med cell Europe,Holostem,Miltenyi Biotec,

With tables and figures helping analyse worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. .

No. of Pages:139

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/1146196

Furthermore, the report provides a detailed analysis of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market with analysis of market size by value and volume. Along with this, an analysis of penetration rate and the average revenue generated per user (ARPU) in the market has also been done. The report also includes a detailed analysis of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market by countries, comprising of its market by value, volume, and ARPU and penetration rate.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-Embryonic Stem CellResident Cardiac Stem CellsAdult Bone MarrowDerived Stem CellsUmbilical Cord Blood Stem Cells

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Autologous Stem Cell and Non-Stem Cell Based Therapies for each application, including-Neurodegenerative DisordersAutoimmune Diseases Cancer and TumorsCardiovascular Diseases

Market Share In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Autologous Stem Cell and Non-Stem Cell Based Therapies Report by Material, and Geography Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

Why To Select This Report:

Complete analysis on market dynamics, market status, and competitive Autologous Stem Cell and Non-Stem Cell Based Therapies view is offered.

Forecast Autologous Stem Cell and Non-Stem Cell Based Therapies Industry trends will present the market drivers, constraints and growth opportunities.

This research report will help to understand how the market will grow in the coming years lets say next 5-6 years and so on.

All vital Autologous Stem Cell and Non-Stem Cell Based Therapies Industry verticals are presented in this study like Product Type, Applications and Geographical Regions.

This in-depth market study will help to analyze the and take informed decision in their respective field.

Order a copy of Report @https://www.orianresearch.com/checkout/1146196

Key Points Table of Contents

Chapter 1 Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Overview

Chapter 2 Autologous Stem Cell and Non-Stem Cell Based Therapies Up and Down Stream Industry Analysis

Chapter 3 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

Chapter 4 2014-2019 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 5 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Key Manufacturers Analysis

Chapter 6 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 7 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

Chapter 8 2014-2019 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 9 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Key Manufacturers Analysis

Chapter 10 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 11 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

Chapter 12 2014-2019 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 13 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Key Manufacturers Analysis

Chapter 14 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 15 Autologous Stem Cell and Non-Stem Cell Based Therapies Marketing Channels Development Proposals Analysis

Chapter 16 Development Environmental Analysis

Chapter 17 Autologous Stem Cell and Non-Stem Cell Based Therapies New Project Investment Feasibility Analysis

Chapter 18 2014-2019 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 19 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 20 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Research Conclusions

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on The World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email:[emailprotected]

See original here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Development, Top Trends and Future Scope with New Industry Opportunities - VaporBlash

Recommendation and review posted by Bethany Smith

Outcome means a special Thanksgiving

Hailie and Treylin Hyman saw the bruising on their baby girls leg as a sign that the active 1-year-old was learning to walk.

But as a blood test would later reveal, little Maci was actually suffering from an extremely rare blood cancer that threatened her life without a risky treatment - atreatmentalmost as dangerous as the disease.

In the beginning, it was very scary, Hailie Hyman told The Greenville News.

I couldnt think of anything but the bad things, she confessed. It was all about the statistics. And the statistics arent good.

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

Terrifying months followed the diagnosis, punctuated by one critical complication after another, leaving the Boiling Springs couple to wonder if Maci would survive.

Somehow, though, the blue-eyed toddler pulled through.And now her family is looking forward to a special Thanksgiving with much to be grateful for.

The Hymans journey began last February atMacis 1-year-old well-child checkup.

We had no idea anything was wrong, her mom said.But they did a routine (blood test) and a couple of hours later, we got a call saying her platelets were very low.

The Hymans were referred to a hematologist who found other abnormalities in Macis blood and scheduled a bone marrow biopsy to investigate further.

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

During the procedure, the child suffered an aneurysm in an artery and went into cardiac arrest. The team performed CPR on her for 20 minutes before she was stabilized, her mom said.

Later, in the pediatric intensive care unit, she suffered internal bleeding, too.

It was really hard, she said. There were many nights that I would just pray and pray and pray.

Initially believing Maci had leukemia, doctors subsequently determined she had myelodysplastic syndrome, or MDS.

The condition occurs when abnormal cells in the bone marrow leave the patient unable to make enough blood, according to the American Cancer Society.

Its rare, afflicting as few 10,000 Americans a year, though the actual number is unknown.

Maci Hyman, 1, interacts with hospital staff before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

In children, its rarer still. Most people arediagnosed in their 70s.

We were told that just four out of 1 million children get it every year, Hailie Hyman said.

That made the diagnosis elusive at first, said Dr. Nichole Bryant, a pediatric hematologist-oncologist with Prisma Health-Upstate, formerly Greenville Health System.

Shes the only one Ive seen in my career, she said.

Maci had to have regular blood transfusions, antibiotics and other medications to fight the MDS, Bryant said. But the only hope for a cure was a stem cell transplant at the Medical University of South Carolina in Charleston.

When they said that was the only treatment plan for MDS, I of course went to Google, Hailie Hyman said. I read about transplant patients and ...all the complications. It was terrifying. But no matter how many bad things I saw, we had to do it. There is no other option.

The transplantis extremely risky.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

First, high doses of chemotherapy are given to destroy the diseased bone marrow, leaving the patient without an immune system, so fighting infections becomes a challenge. Then healthy donor marrow is infused.

Its also fraught with potentially life-threatening complications, including graft vs. host disease, which occurs when immune cells from the donor attack the patients body, Bryant said. Other complications include permanent kidney damage and gastrointestinal problems.

They have to go to hell and back, she said. But its the only option for long-term survival.

Maci had a really rough start, suffering lots and lots and lots of complications, Bryant said.

Her kidneys failed, so she wound up on dialysis. When she couldnt breathe on her own, she was put on a ventilator. And because she couldnt eat, she had to be tube fed.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

She had blistering sores in her mouth and throughout her GI tract, her mom said. Because her liver wasnt functioning properly, her abdomen filled up with fluid that had to be drained. She was bleeding so profusely in her lungs that one of them collapsed.

Maci, who was sedated through much of it, was put on full life support, she said.

That night we almost lost her, her mom said. We were in the hallway crying our eyes out. We didnt know what do to or think. It was pretty scary for a while.

Somehow, Maci made it.

There were so many times during her first months that it seemed like she would not survive, Bryant said. So the fact that she is here ... is really a miracle.

Macis family found an unrelated donor through the National Marrow Donor Program, enlisting hundreds of other people to join the registry in the process, Bryant said.

Nichole Bryant, M.D.(Photo: Provided)

It was an important part of their journey that maybe didnt directly benefit Maci, she said. But if everybody did that, we wouldnt have difficulty finding a donor for anybody.

Doctors have no explanation for why Maci got MDS. She didnt carry the genetic mutation for it and there is no family history.

She is a rare child - and not in a good way, her mom said, adding,Youve got to laugh sometimes or youre going to cry.

Maci was admitted to MUSC on June 2 and released on Oct. 14.

The Hymans, both 22, spent the entire time in Charlestonwhile Hailies mom cared for their older daughter, Athena, now 2.

Treylins employer held his welding job open for him. And other friends and family members did what they could to help.

We had many, many people very generously donate to us to cover expenses at home and living expenses where we were, Hailie Hyman said.

We are thankful for everyone who helped us through it the cards, the gifts, the donations. Every single cent is greatly appreciated.

They still need to travel to Charleston once a week to see the transplant doctor. In between, Maci is seen in Greenville.

She's doing well, but recovery from a transplant can take months to years, Bryant said.

NEWS CHECKUP

Get more news about developments in health andpatient care at the local, state and national level. Pleaseconsider becominga subscriber. Here's our special offer.

Her kidneys are functioning again so she was able to come off dialysis. But she still must take many medications, including anti-rejection drugs that suppress her immune system and leaveher at risk for infection. And she still must be tube fed.

She is miles ahead of where she was two months ago, Bryant said. But she still has a long way to go. Its a long, long road.

Macis mom says she can be up and playing one day and flopped over on the couch another. She still experiences a lot of nausea and vomiting, but is doing well compared to where she was.

Hailie Hyman pulls her daughter Maci, 1, in a wagon in the hallway before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

So as the nation pauses to give thanks this Thanksgiving, she says the family will be countingtheir many blessings family andfriends, Gods mercy, andthe doctors and nurses who saved Macis life.

She has battled a lot and overcome a lot, she said. I have no doubt she will be able to get through.

Want to know more about becoming a marrow donor? Go to bethematch.org.

Read or Share this story: https://www.greenvilleonline.com/story/news/health/2019/11/27/upstate-sc-toddler-survives-rare-cancer-and-risky-procedure-treat/4158606002/

Continued here:
Upstate SC toddler survives rare cancer and the risky procedure used to treat it - Greenville News

Recommendation and review posted by Bethany Smith

Collagen seems to be one of the buzziest words in wellness, with just about anyone's ears perked up at the mention of the wordno matter how young they are. Because when it comes to healthy skin aging, we know that prevention is everything, and delaying the process before it starts is key to maintaining a smooth, even complexion well into the autumn of life.

Enter all the collagen-promoting creams, serums, supplements, and diets the world has to offerand now, a new drug may be just the trick.

A new study published in the journal GeroScience found a new, unexpected formula to help with healthy aging. This specific drugcalled rapamycinhas been primarily used for patients who have undergone an organ transplant, as it helps prevent the immune system from rejecting the new organ. Rapamycin has also been used to combat a rare lung disease called lymphangioleiomyomatosis, as well as inhibiting tumor growth.

Read this article:
Study Finds This Medication May Reduce Wrinkles & Even Skin Tone - mindbodygreen.com

Recommendation and review posted by Bethany Smith

When it comes to our beauty and skincare products, it's easy for years to pass without an updateor even an upgrade. But because advances in beauty technology are happening at the speed of light, its always important to pause and reassesswhat we're usingfrom dog shampoo to stem-cell skincare. SoI've rounded up the best of the latest trends that have earned a place inmymakeup bag.

Its no secret that Ima major fan of Kjaer Weisthere is something utterly fresh and clean about everything for the face and body, and its as organic as it can get. Enter the latest additions to the line: the cleanser ($95) and toner ($85, both pictured above). Not only does the soft, gel-like cleanser effectively remove all makeup, but its also calming. Follow it with a quick spritz of the toner and you have hydrated and re-balanced skin. Plus, the scents aredreamy.If I could accurately describe them, I would. But I was in Bluemercury downtown recently they have sample bottles to give it a go yourself.Bluemercury, 1500 Main Street, Sarasota. (941) 365-0020

Two things on my must-do-better list: Sunscreen and preventing this neck from aging. Addressing the first, Alastin Skincares HydraTint Pro Mineral Sunscreen SPF 36 ($55) is a revelation. Not only is it lightweight, with broad-spectrum UVA/UVB sun protection, it also protects against environmental pollution and it has a universal tint that enhances most skin tones. Its the first thing Iput on in the morning before taking the dogs for a walk; I love the just-right tinted coverage.

Second, that neck thing. As much as I prefer organic and natural skincarewhen possible, I tend to lean on science for combatting aging. Enter: Nectifirm Advanced ($133). Its next-gen technology based on the ecosystem of the skins microbiome, plus eight peptides that helps skin appear firmer and lifted while lessening the appearance of lines and wrinkles. Not to mention that those in the know at Sarasota Facial Aesthetics rave about the results. Get both products atSarasota Facial Aesthetics,1806 South Osprey Avenue,(941) 955-8384.

I was of the mind that a razor is a razoris a razor. Well, thats changed since theFlamingo razor($9.99) came on my radar. The team raised the bar on shaving after spending years talking to women (what a concept!) who shared the nuances of their personal care rituals and how typical razors fell short. Use this once and it will be clear that they did not overlook those edges of our bodies that need extra attention.Target, 101 N. Cattlemen Road, (941) 360-7520

Speaking of: here's another kind of sunscreen, this time for the eye area. Who knew? I recently discovered Colorescience Total Eye3-in-1 Renewal Therapy SPF 35 ($74)they say it visibly improves the appearance of dark circles, puffiness, fine lines and wrinkles, while protecting the delicate eye area against photoaging with 100 percent SPF 35 mineral sunscreen. I say its great coverage, and if it comes with all of those benefits then...yay!L. Spa, 556 Pineapple Ave., (941) 906-1358

Brace yourself (and maybe your credit card) because Augustinus Baders The Cream ($265) is right there at the cutting edge for stem cell skincare. Get this: the stem cells found in skin lie dormant, awaiting an activation signal to repair the damage inflicted by life and environmental factors.The patented technology TFC8Bader's proprietary "Trigger Factor Complex"is comprised of natural amino acids, high-grade vitamins and synthesized molecules that are found naturally in the skin. Its a repairing force in an ultra-lightweight cream that guides key nutrients and powerful natural ingredients to the skin cells, creating an optimal environment for the body's innate processes of repair and renewal.Thats a lot, but all I know is that I can see the results after a lotta life has happened to my skin. Its crazy good, and I guess for the price it should be. Saks Fifth Avenue, 120 University Town Center Drive, Sarasota. (941) 364-5300

Lastly, this one is for the love of our fur kids, especially those with sensitive skin. The Malin + Goetz Dog Shampoo ($28) is infused with natural botanical amino acids to gently cleanse fur and skin without drying, stripping or irritating. And I can attest that fur dries soft and oh-so-shiny. Malin + Goetz, malinandgoetz.com

Read this article:
Seven Products Our Beauty Editor Used to the Last Drop - Sarasota

Recommendation and review posted by Bethany Smith

Soon youll be able to cover your imperfect flesh with more flesh. (Photo: KaoJapan)

FOX NEWS - Soon youll be able to cover your imperfect flesh with more flesh.

Japanese cosmetics company Kao Corporation has developed a custom synthetic spray-on skin to cover unwanted blemishes, moles or other marks on the natural epidermis.

READ MORE ON FOXNEWS.COM

The artificial product, called est, is composed of tiny, liquid fibers. When sprayed, the substance adheres to human skin, transforming into an extremely thin, derma-like material, the Daily Mail reports.

It has a similar elasticity to skin, and its porous, too. Water vapor and air can pass through this second skin to moisten the living dermis beneath. At its edges, est forms an even thinner bond, helping it blend in with natural flesh.

Est is set to hit the market exclusively in Japan beginning Dec 4. and will sell for roughly $532 as a diffuser and potion combination, with diffuser refills priced at $73. A lotion version will sell for $110, and everything will become available online in January, according to Japanese publication the Asahi Shimbun.

Japanese-language advertisements for the product call it Future Skin, which uses Fine Fiber Technology. Kao has plans to expand the line beginning next year and hopes to soon enter the medical market.

Until then, American consumers can check out the SkinGun by RenovaCare, which shoots a liquid mist infused with human stem cells and can help burn victims skin.

CHECK FOR UPDATES ON FOXNEWS.COM

Read this article:
Makeup brand offers spray-on 'skin' to cover up zits and scars - FOX 10 News Phoenix

Recommendation and review posted by Bethany Smith

Were always happy to geek out over a buzzyskin careingredient when we see it making the rounds on product labels. (See: lactic acid, rosehip oil, bakuchiol) So when we started noticing the proliferation of niacinamide, we were surprised to learn that not only has it been around for a while buttheres a decent body of research behind the multipurpose vitamin. Heres what you need to know about niacinamidesbenefits for your skin.

Niacinamide, a form of vitamin B3 also known as nicotinamide, is a water-soluble vitamin that has potent antioxidant activity and reduces inflammation, saysboard-certified dermatologistDavid Lortscher, CEO of Curology.

It would be an exaggeration to call niacinamide a cure-all, but it does have a pretty extensive range when it comes to the conditions it can treat: acne, oil regulation, fine lines and wrinkles, hyperpigmentation, enlarged pores and sun damage. Its especially good at repairing skins moisture barrier (aka its first line of defense) and protecting against environmental stressorsits even been shown to help prevent skin cancer in certain studies.

Niacinamides nourish and calm redness and inflammation,says DendyEngelman, a board-certified dermatologist in New York. She particularly likes niacinamide for dry and sensitive skin: It has similar effects to retinol by strengthening the skin barrier, but itfortifies from the get-go without sensitivity or irritation.Dr. Lortscher also has high praise: Because of its role in repairing the skin barrier, niacinamide is one of the most effective treatments for photoaging [damage caused by UV rays], according to most anti-aging research.

It starts to get technical here, but as Dr. Engelman explains it, Niacinamide helps support the cellsmetabolic system, specifically fibroblasts. We use fibroblasts tomake and repair DNA,which,in turn, activates collagen production. So by using niacinamides to boost fibroblast production, we are supporting collagen production and repairing damaged collagen.

Lots of products contain niacinamideserums, moisturizers, even cleansersand it works well in conjunction with other active ingredients, like retinol. It can be used both morning and night, though as with any goodskin careregimen, you should follow it up with a sunscreen during the day.

Niacinamide should be compatible with most otherskin careproducts and is well tolerated by all skin types,including sensitiveskin, Dr. Lortscher says. For best results, use leave-on products with niacinamide. Its safe to use around the eyes, anditmay improve the appearance of under-eye darkness and wrinkles.

Convinced yet? Check out a few of our favorite products containing the powerhouse ingredient below.

RELATED: We Ask a Derm: What Ingredients Should You Avoid If You Have Oily Skin?

Of course, the uber-popular, wallet-friendly brand is on top of it. This serum is especially helpful for congested, acne-prone skin: The niacinamides anti-inflammatory propertiescalm active breakouts, while its oil-regulating properties (and the addition of zinc, which also keeps oil in check) help keep new ones from forming.

Buy it ($6)

Nia 24 uses a patented form of niacinamide thats designed to absorb better into skin (and therefore work its magic more effectively). This rich cream strengthens the skin barrier with its namesake ingredient, plus hyaluronic acid, licorice root extract, peptides and ceramides.

Buy it ($118)

Give parched, dull skin a quick pick-me-up with a five-star-rated gel sheet mask. Reviewers rave about its glow-inducing, hydrating properties and the fact that its gentle enough for sensitive skin.

Buy it ($3)

Cursed by the ghosts of pimples past? Niacinamide, glycolic acid and NASA-developed plant stem cells (!) work together to combat hyperpigmentation and scarring.

$20 on Amazon

Derms, dry-skinned gals and makeup lovers alike know oil cleansers are a godsend forwashing off the days makeup withoutstripping any precious natural moisture. This cleanser amps up the effects with niacinamides barrier-strengthening effects, plus offers a gentle exfoliation thanks to fruit enzyme.

Buy it ($42)

SkinCeuticals serums are cult faves for a reason, and this 5 percent niacinamide serum is no exception. Its amped up with amino acids, algae extract and peptides to target the effects of environmental stress and promote collagen production.

Buy it ($112)

RELATED: The Best Face Moisturizer for Dry, Sensitive Skin, According to People Who Use Them

See the original post:
Heres How Niacinamide Benefits Your Complexion (and How to Work It into Your Skin Care Routine) - Yahoo Lifestyle

Recommendation and review posted by Bethany Smith

Birds of a feather may flock together, but the feathers of birds differ altogether.

New research from an international team led by USC scientists set out to learn how feathers developed and helped birds spread across the world. Flight feathers, in particular, are masterpieces of propulsion and adaptation, helping penguins swim, eagles soar and hummingbirds hover.

Despite such diversity, the feather shares a common core design: a one-style-fits-all model with option trims for specialized performance. This simplicity and flexibility found in nature holds promise for engineers looking for better ways to build drones, wind turbines, medical implants and other advanced materials.

Those findings, published today in Cell, offer an in-depth look at the form and function of a feather based on a comparative analysis of their physical structure, cellular composition and evolution. The study compares feathers of 21 bird species from around the world.

Weve always wondered how birds can fly in so many different ways, and we found the difference in flight styles is largely due to the characteristics of their flight feathers, said Cheng-Ming Chuong, the studys lead author and a developmental biologist in the Department of Pathology at the Keck School of Medicine of USC. We want to learn how flight feathers are made so we can better understand nature and learn how biological architecture principles can benefit modern technology.

To gain a comprehensive understanding of the flight feather, Chuong formed a multi-disciplinary international team with Wen Tau Juan, a biophysicist at the Integrative Stem Cell Center, China Medical University in Taiwan. The work involved experts in stem cells, molecular biology, anatomy, physics, bioimaging, engineering, materials science, bioinformatics and animal science. The bird species studied include ostrich, sparrow, eagle, chickens, ducks, swallow, owl, penguin, peacock, heron and hummingbird, among others.

They compared feathers using fossils, stem cells and flight performance characteristics. They focused on the feather shaft, or rachis, that supports the feather much like a mast holds a sail, bearing the stress between wind and wing. They also focused on the vane, the lateral branches astride the shaft that give the feather its shape to flap the air. And they examined how evolution shaped the barbs, ridges and hooks that help a feather hold its form and lock with adjacent feathers like Velcro to form a wing. The goal was to understand how a simple filament appendage on dinosaurs transformed into a three-level branched structure with different functions.

We want to learn how flight feathers are made so we can better understand nature and learn how biological architecture principles can benefit modern technology.

Cheng-Ming Chuong

For birds such as ducks, eagles and sparrows that fly in different modes, the scientists noted significant differences in the feather shaft compared to ground-hugging birds. On the rigid exterior, the shaft cortex was thinner and lightweight, while the interior was filled with porous cells resembling bubble wrap, aligned into bands of various orientations and reinforced with ridges that operate like tiny lateral beams. Together, it forms a light, hollow and buoyant structure to enable flight. Cross-sections of feather shafts of different birds show highly specialized shapes and orientations of the inner core and outer cortex.

The flight feather is made of two highly adaptable architectural modules, light and strong materials that can develop into highly adaptable configurations, Chuong said.

The researchers discovered two different molecular mechanisms guiding feather growth. Cortex thickness was governed by bone morphogenetic proteins, which are molecular signals for tissue growth. The porous feather interior, or medulla, relied upon a different mechanism known as transforming growth factor-beta (TGF-b). Both components originate as stem cells in the birds skin.

By contrast, feathers in flightless birds were simpler, consisting of a dense cortex exterior that is more rigid and sturdy with fewer internal struts and cells found in flying birds. The features were especially pronounced for penguins, which use wings as paddles under the water.

As part of the study, the researchers looked at 100 million-year-old feathers, found embedded in amber in Myanmar. These fossils show early feathers lacked one key feature that modern birds have. Specifically, the researchers report that fossil feathers had barb branches and barbules, which form a feather vane by overlapping, but not hooklets. The hooklets, which act like clasps to turn fluffy feathers into a tight flat plane for high-performance flight, evolved later. The scientists also identified WNT2B, another growth factor, as the agent that controls hooklet formation. These also originated from epidermal stem cells.

Taken together, the findings show how feathered dinosaurs and early birds could form a primitive vane by overlapping barbule plates, although that wasnt aerodynamically fit to carry much load. As more complex composite features occurred in the wing, it got heavier, so feather shafts became stronger yet more lightweight, which led to stiffer feathers and sturdy wings that powered flight to carry birds around the world.

Our findings suggest the evolutionary trends of feather shaft and vane are balanced for the best flight performance of an individual bird and become part of the selective basis of speciation, the study said. The principles of functional architectures we studied here may also stimulate bio-inspired designs and fabrication of future composite materials for architectures of different scales, including wind turbines, artificial tissues, flying drones.

Chuong and Juan are co-leaders of the 31-person team, joined by co-authors Randall B. Widelitz, Shuo Wang, Michael Habib, Ting-Xin Jiang, Zhong-Lai Luo and Ping Wu of the Keck School of Medicine of USC; Wei-Ling Chang, Hao Wu, Yung-Chi Lai, Ming Xing Lei, and Shih-Chieh Hung of the China Medical University Hospital in Taiwan; Ming-You Shie, Jui-Ting Hsu, Heng-Li Huang and Yi-Wen Chen of the China Medical University, Taiwan; Chih-Feng Chen, Ping Chi Tang, Hus Chen Cheng, and Yen-Cheng Lin of the National Chung Hsing University in Taiwan; How-Jen Gu, Yu-Kun Chiu, Tse-Yu Lin, Shun-Min Yang, Tsung-Tse Lee, J.C. Tsai and Yeu-Kuang Hwu of the Institute of Physics, Academia Sinica, Taiwan; Cheng-Te Yao of the Endemic Species Research Institute, Taiwan; Shyh-Jou Shieh of the National Cheng Kung University, Taiwan; Ang Li of the University of Texas, Arlington.

Work at USC was supported by the National Institutes of Health (AR 047364, AR 060306) while team members in Taiwan were supported by grants from their own institutes and the Taiwan government.

More stories about: Biology, Research

Read the rest here:
How birds fly: New USC study examines the evolution of flight feathers - USC News

Recommendation and review posted by Bethany Smith

ANI | Updated: Dec 02, 2019 12:06 IST

New Delhi [India], Dec 2 (ANI): Although business conditions in the Indian manufacturing sector improved in November, the upturn remained subdued compared to earlier in the year and the survey history, according to IHS Markit India Manufacturing Purchasing Managers' Index (PMI) released on Monday.Growth rates for new orders and production were modest despite accelerating from October's recent lows while firms shed jobs for the first time in 20 months and continued to reduce input buying.At the same time, there were only slight increases in input costs and output prices halfway through the third quarter of fiscal year 2019-20.The headline seasonally adjusted IHS Markit India Manufacturing PMI rose from 50.6 in October, when it had fallen to a two-year low, to 51.2 in November. The latest reading was below the survey average (53.8) and indicated only a slight improvement in the health of the sector.Consumer goods provided the main impetus to overall growth while the intermediate goods category returned to expansion territory. Conversely, there was a solid deterioration in operating conditions at capital goods makers.Indian manufacturing production increased only moderately in November, albeit at a quicker rate than October's two-year low.Anecdotal evidence suggested that growth was supported by the launch of new products and better demand, though restrained by competitive pressures and unstable market conditions.Total sales increased for the 25th month in a row with growth strengthening from October's recent low. Besides, the upturn was among the weakest over this sequence.Some firms were able to secure new work amid successful marketing and strengthening demand, but others struggled in the face of competitive conditions, a challenging economic scenario and troubles in the automotive sector.Manufacturers were partly helped by external markets as signalled by a further expansion in international sales. The increase in exports was slight, however, and among the weakest over the past year-and-a-half."PMI data continued to show a lack of inflationary pressures in the sector which, combined with slow economic growth, suggests that the Reserve Bank of India will likely extend its accommodative policy stance and further reduce the benchmark interest rate during December," said Principal Economist at IHS Markit Pollyanna de Lima.Subdued sales prevented hiring in November with payroll numbers declining for the first time in 20 months. A number of companies indicated that workloads had been managed by existing staff while others cited the non-replacement of retirees and non-renewal of temporary contracts.Firms also scaled back input purchasing, with the latest decline the fourth in as many months. Subsequently, the current sequence of falling stocks of purchases that started in August was extended to November.Rates of contraction for both input buying and inventories were marginal, said IHS Markit.The IHS Markit India Manufacturing PMI is compiled from responses to questionnaires sent to purchasing managers in a panel of around 400 manufacturers. The panel is stratified by detailed sector and company workforce size, based on contributions to GDP.IHS Markit is a world leader in critical information, analytics, and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics, and solutions to customers in business, finance, and government. (ANI)

Read more from the original source:
Production growth strengthens in November but remains subdued: IHS Markit - ANI News

Recommendation and review posted by Bethany Smith

Saggy, wrinkled faces could soon be a thing of the past as researchers have identified a key mechanism of how skin ages.

A key protein compound which could represent a new anti-ageing intervention has been discovered by scientists.

Two drugs have been created which offer hope that a fountain of youth could be developed in the future.

The drugs work by boosting levels of a certain protein, which is found in high levels in young skin cells, but begins to dwindle over time as we age.

When the levels of this protein drop, skin cells appear older, misshapen and less elastic.

They also appear thinner and become more blotchy and more fragile.

As long as lots of cells are being born deep below the surface of the skin with high levels of the protein, the skin appears youthful.

In a survival of the fittest scenario, these healthier skin cells out-compete the weaker ones, which go on to die.

But over time, fewer strong skin cells are born and the weaker ones take over, creating a wrinkly appearance to the skin.

In addition, stress, such as exposure to toxic chemicals, or sun damage can also reduce levels of the protein, called COL17A1.

But giving hope to anyone who wishes for a more youthful appearance, researchers said they have found a way to boost its levels.

As well as recreating youthful looks, the drugs have potential to help wound healing and even to prevent skin cancer, the researchers suggest.

Emi Nishimura, from Tokyo Medical and Dental School, and colleagues made the discovery in mice and in human skin tissue grown in the laboratory.

The compounds have yet to be tested on living humans.

Writing in the journal Nature, the authors said they discovered two chemical compounds that boosted COL17A1.

The chemicals, Y27632 and apocynin, when applied to the skin, significantly promoted wound repair by boosting the production of skin cells with high levels of COL17A1, the authors wrote.

The discovery points towards directions for facilitating skin regeneration and reducing skin ageing, they said.

Commenting on the discovery, Ganna Bilusova and James DeGregori, both of the University of Colorado, suggest that the discovery may also help prevent tumours forming.

They wrote, the maintenance of fit stem cells through the years in which an individual is likely to reproduce probably also prevents tumour development, because these fit cells compete with (and eliminate) both damaged stem cells and tumour-prone cells.

They added that the work provides evidence that healthy cells in mammals can also efficiently repopulate adult tissues, replacing unfit or damaged cells.

Both chemicals improve wound healing in mouse tail skin, providing a proof-of-principle demonstration of the therapeutic potential of this new class of drug.

The development also points the way to regenerate other organs apart from the skin, Professor Bilusova and Professor DeGregori wrote.

Future studies are needed to determine the mechanisms of cell competition in other tissues, and to identify compounds capable of reversing ageing in other organs.

Wrinkles are creases, folds, or ridges in the skin.

They normally appear as people get older, but they can also develop after spending a long time in water.

The first wrinkles to appear on a persons face tend to occur as a result of facial expressions.

A tendency to laugh, frown or glare in a certain way can amplify creases in particular regions.

Laughter lines and crows feet tend to be formed from smiling and forehead furrows originate from frowning.

Sun damage, smoking, dehydration, some medications, and environmental and genetic factors also affect when and where people will develop wrinkles.

Most wrinkles tend to appear in the parts of the body which receive the most sun exposure, especially the face and neck, the back of the hands, and the arms.

The upper layer of skin has to renew regularly as it is made of dead cells.

As you get older, it takes longer for your epidermis to renew itself and it shows more and more signs of your age.

Go here to see the original:
Scientists create drugs to keep the skin youthful by boosting levels of a crucial protein - Stock Daily Dish

Recommendation and review posted by Bethany Smith

Mucopolysaccharidoses (MPS) are a group of very rare disorders, also known as orphan diseases. They belong to the group of lysosomal storage diseases which are caused by a deficiency of one of the enzymes involved in the degradation of mucopolysaccharides (the acid glycosaminoglycans or GAGs). The enzymes are coded by genes which produce deficient gene products due to gene variants in each of the two gene-alleles.

Children of two carriers as parents have a 25% risk to suffer from MPS. For many families, the birth of the first affected child is a shock and a disaster. The disease is continuously progressing, and life spans are dramatically decreased without therapy. As a result, extensive efforts are put into the cure of these fatal disorders.

Enzymes are relatively small proteins, produced in the endoplasmatic reticulum of each cell. Before reaching the locus of their function, the lysosomes, additional modifications with special sugars are performed in the Golgi apparatus (glycosylation). Via mannose-6-phosphate marker, they connect to the mannose-6-phosphat receptor on the lysosomal membrane and can reach the final locus of their function. In the lysosomes, enzymes degrade the GAG chains into the smallest molecules for recycling or excretion. Any disturbance in this process leads to the accumulation of non-degraded material, which affects many other cell functions such as homeostasis, calcium metabolism, accelerates apoptosis and induces inflammation processes.

As lysosomes are ubiquitous, any disturbance leads to storage in many different tissues and organs. MPSs are a good example for chronic progressive multi-systemic disorders. The best theoretical option for treatment of any patient is to supplement the missing enzyme which could reach any organ via blood flow and get inside the lysosomes continuing the interrupted degradation processes.

The enzymes are ubiquitous and have some tissue specific compositions. Enzymes produced in the different cells and tissues have their own characteristics and are available on site. The production of recombinant enzymes means that the artificial glycosylation is created in a uniform composition for intravenous substitution with the aim to reach the organs with the blood-flow. There is no doubt that the therapeutic efficacy is ideal for many organs, such as liver, spleen, lung, and skin. All these organs have a good blood circulation and some ability to regenerate.

However, after years of treatment with the already available enzymes, it is shown that some organs are poorly supplied with blood and renewal cycles are slow, the ability to regenerate is decreased. Organs such as bones, cartilage, muscles, cornea, heart valves, meninges or the brain do not show the hope-for effect. All MPS types with brain involvement (neuronopathic forms of MPS types I, II and VII) or predominant skeletal dysplasia (MPS types IVA and B) cannot benefit from enzyme-replacement therapy and do not show the desired improvement.

In animal studies, modifications of glycosylation can change the ability to pass into organs not yet sufficiently reached such as cartilage or bones, but tissue-specific features cannot be sufficiently considered in any artificial production of the enzymes.

Avascular cartilage, heart valves and corneas cannot be reached by blood flow. Also, between blood vessels and brain tissue, several specialised cells form the blood-brain-barrier (BBB) to protect the brain from any unwanted substances in the blood. Therefore, new strategies are necessary to improve the therapeutic efficiency and to provide better outcomes for the affected patients. If patients with MPS I are diagnosed at a very young age, the best option is to treat them with haematopoietic stem cell transplantation (HSCT). Migrating stem cells can reach the brain and other organs, and then differentiate into organ-specific cells producing the missing lysosomal enzymes.

A straightforward method to overcome BBB is the direct injection of a recombinant enzyme into the cerebral fluid. This can be by lumbar puncture (intra-thecal) or intra-ventricular injections in the brain ventricles. Effects can be observed, however unfortunately not all challenges can currently be solved. The liquor flow can be reduced by thickened meninges with storage and vertebral deformities, which are typical for the disease. However, the barrier between cerebral fluid and brain tissue has still not been fully studied. The half-life of enzymes is limited, and the procedure has to be repeated regularly. The clinical trials for patients with MPS I, II, IIIA and IIIB could show some reduced or reversed progression of CNS pathology but long-term effects remain unclear.

Another possibility to overcome BBB is to fuse the enzyme proteins with macromolecules which enter the brain through receptor mediated active transport systems. This physiological transport is known for hormones, neurotransmitters and many other proteins (such as transferrin and insulin). They are transported through the BBB directly into the brain via specific receptores, so, the strategy is to fuse the natural proteins with the artificial enzymes needed in the MPS patient. It is important to note that clinical trials could potentially still show some improvement in affected MPS patients.

Another method is to conjugate the therapeutic enzymes with nano-capsules and to then ferry them across BBB via transcytosis or other transport mechanisms directly into brain cells. Pharmacological chaperones have been proven to be effective in other lysosomal storage diseases such as Gaucher or Fabry disease. Chaperones are able to stabilise three-dimensional conformation of misfolded proteins, such as enzymes. This would be the case of genetic variants causing missense mutation and exchange of only one amino acid in the protein chain. The misfolding pathology reduces stability, half-life and effect of the genetically conditioned enzyme, whereas the chaperone can reverse this disadvantage and increase the activity and efficacy of the enzyme. As a result, pharmacological chaperones are a good option for some diseases and could therefore be an option for some MPS patients in the future.

Some genetic variants cause stop-codons and the production of truncated dysfunctional peptides without any enzymatic activity and degradation within the cell. Stop-codon read through therapy aims for the genetic correction on an RNA level, resulting in the production of a sufficiently functioning gene product. It is already used for some specific mutation for patients with Duchenne muscular dystrophy, but it is too early to predict positive results for patients with MPS I.

Another possibility in the future might be the use of GAG-reducing small molecules such as Genistein, Pentosam polysulfate or Rhodamine B. They are able to influence and/or reduce the synthesis of GAGs which cannot be degraded sufficiently by the genetically changed enzymes with reduced function.

To reduce the GAGs as substrate, could be a chance to create a better relation between substrate and the impaired substrate reducing enzyme. As a result, lysosomal storage could therefore be reduced. Substrate reduction therapy is an established therapeutic concept in some of the other lysosomal storage diseases, but the usefulness in MPS disorders still needs to be proven.

The genetic corrections of DNA sequences in patient cells are no longer only future options as they have now become a reality. Gene variants causing missing or impaired functioning gene products could be replaced by correct genetic sequences and genes. This can be made as an ex vivo approach, where stem cells or fibroblast are removed from the patient and are then cultured in vitro, genetically corrected and consecutively re-injected into the patient.

The genetically corrected DNA in the re-transplanted autologous cells is able to produce correct gene products (in terms of MPS, this is the specific enzyme). The amounts of newly produced enzymes might be sufficient to positively influence the disease course of the treated patients.

An in vivo approach utilises viral vectors which invade cells, and even cell nuclei. Such viruses used are adeno-associated-viruses or lenti-viruses. Such manipulated viruses with the corrective genetic material are directly injected into the patient where they are internalised into deficient cells and are then able to produce the missing gene product. In the case of MPS, the aim is to produce enzyme proteins with sufficient concentrations and activity to prevent the storage of GAGs. Furthermore, clinical trials are underway for several MPS types and therefore, might offer a therapeutic opportunity in early life for affected patients. However, larger studies and a longer follow-up is still needed.

To conclude, MPS are rare genetic disorders and for a long time, they were linked with the myth of being untreatable diseases. Although some of the new therapeutic options are still in clinical trials and not routinely used, the present shows that many of the patients can benefit from the yet available options of HSCT and enzyme replacement therapies. These therapies have an undoubted effect for some of the MPS patients, especially if any form of therapy is started early or if the course of the disease does not affect the nervous system.

However, in the future, new therapeutic options will hopefully bring benefits to those that are not sufficiently improved; the decision of the best therapy will be made on the basis of factors such as the genetic defect, the type of MPS, and the age during treatment. This individualised and personalised therapy will improve the success of MPSs therapies.

Susanne Gerit KircherMedical University of Vienna, AustriaCenter of Pathobiochemistry and Geneticssusanne.kircher@meduniwien.ac.atwww.mps-austria.at

Excerpt from:
Mucopolysaccharidoses: future therapies and perspectives - SciTech Europa

Recommendation and review posted by Bethany Smith

Bioidentical Hormone Doctors: How to Choose

There are many bioidentical hormone doctors to choose from, and after the initial questions about how long they have been practicing and their specialties, there still may be a lot of decisions to be made. So how to you choose among all of these bioidentical hormone replacement therapy doctors for the one that is the right fit for you? We want to provide that advice but also to start with the fact that often the best advice about potential bioidentical hormone doctors comes from word of mouth and reputation. Aside from that there are other steps you can take to choose, and we want to help. Please understand that we are a fully independent website and in order to stay completely unbiased we will not recommend any specific doctor or practice.

Lets start with where you want to end up as far as the bioidentical hormone replacement practitioner that is best for you. First, you want someone who has experience, and specifically experience with the type of treatment you need. You also want someone with experience with people your age and gender. So the first question you should ask when you are interviewing potential bioidentical hormone doctors is about their specific experience with people with your presentation. Know how many people theyve treated, and then it may take a few phone calls to be able to compare and contrast.

Once youve narrowed the field to bioidentical hormone doctors who seem to have experience with people like you, you then want to know their success rate. Now of course this is quite tricky since most bioidentical hormone replacement doctors will report a high success rate, so you may want to ask if theyve ever done a customer satisfaction survey. You might also want to see if their practice is covered by any independent review websites on-line. If you can ask a specific question you may be able to get a more concrete answer, such as whether they asked any specific symptom related questions before and after the treatment, and how often the answers were affirmative.

Of course choosing a practitioner can also be a gut level choice, and we do not want to underestimate that factor. The process of BHRT can be long, since even if the practitioner gets things right pretty quickly there is still a chance that you might need additional treatment at some point even if just a booster. Choosing a practitioner who is smart and experienced is important, but you also need to work with someone you feel is approachable, truly hears you, and takes time to understand your symptoms. These qualities may be a little harder to measure, but they are equally important.

With all the advances in social media and communication technology such as websites where you can providefeedback, there is still one method of gathering information and advice about potential medicalpractitioners, bioidenticalor otherwise, and that is word of mouth. It is impossible to know whether ratings sites have been edited or modified or even contributed to by the practitioners themselves, and relying on the comments of people you dont know is suspect anyway. Reputation remains king.

So what if you are the first among you friends and relatives to consider bioidenticalhormone replacement therapy. You can first turn to your PCP or other medical specialists youve seen, as well as friends of your family who are in the medical field to see if they have names of bioidenticalpractitioners. If you come up empty it may be time to interview a few practitioners, and here is what you want to do:

These are just a few steps you can take to check out your prospective bioidenticalhormone replacement doctor, but again, its best if you hear good things from unbiased and randomly chosen people who have seen him or her like your own friends, colleagues and family.

Here are some websites that might help:

Of course the first thing you should ask are questions about your potential doctors background with BHRT. Bioidentical hormone doctors range from having been in the field of BHRT for many years, and being relatively new to the field. The way you digest the answer to this question may not be as simple as it seems. Experience is of course good, but make sure that any bioidentical hormones therapy doctors you choose who have been doing this for a while have also kept up with the very latest techniques and improvements in the field.

You should also ask how much of your practitioners practice is dedicated to BHRT. There are some who do BHRT full-time, while other make it only a fraction of their practice. While you may not necessarily need a practitioner who does it full-time, you do want someone who makes it a large part of their practice. Also, while it may be okay to have some of the procedures performed by a nurse or other trained practitioner, you should make sure that there is a doctor actively involved in following your case and that you will get to meet with her or him regularly. If the physician will not be regularly involved with administration, ask how easy it will be to contact him or her should you have a question or concern, and again how involved she or he will be in reviewing your progress.

Please feel free to use our comments section to relate your own experience in choosing among bioidentical hormone doctors.

Read more:
Finding the Best Bioidentical Hormone Doctors in 2020

Recommendation and review posted by Bethany Smith

If youre considering hormone replacement therapy (HRT), youll want a highly qualified doctor to help you make the decision. What types of doctors prescribe HRT and how do you find the best one for you? Here are important factors to keep in mind.

The following doctors prescribe hormone replacement therapy (HRT) for menopause:

Any of these types of doctors can help you through menopause. Your job is to find the one who best meets your needs. Here are five steps to finding the best doctor to help you manage your menopause symptoms.

Find a doctor who:

Start by creating a list of potential doctors. Ask your family, friends, and other healthcare providers for recommendations. If youre starting without any referrals, or youre looking for more options, search for doctors on Healthgrades.com.

Healthgrades.com shows patient satisfaction ratings, which give you insight into how your own experience might be with the doctor. Patients rate the doctor and the doctors medical practice, and say if they would recommend the doctor to family and friends.

Take time to research the doctors credentials and experience. Look for a doctor who is board certified and cares for women in menopause on a regular basis. The more experience a doctor has treating your condition, the better prepared he or she is to advise you on the best type of hormone replacement based on your individual circumstances.

Also, confirm that the doctor is in good standing with state and federal agencies and that he or she has no history of malpractice claims or disciplinary actions.

Youll find all this information on Healthgrades.com.

As you narrow down your list of doctors, call each office and ask for a consult appointment to meet and interview the doctor.

Here are some questions to ask the doctor:

Your insurance coverage is a practical matter. To receive the most insurance benefits and pay the least out-of-pocket for your care, you need to choose a doctor that participates in your plan.

But keep in mind, just because a doctor participates in your insurance plan doesnt mean he or she is a high-quality doctor. You still need to consider the doctors experience and expertise.

Continue reading here:
Types of Doctors Who Prescribe Hormone Replacement Therapy ...

Recommendation and review posted by Bethany Smith

Ilyse Hogue, president of the abortion rights organization NARAL Pro-Choice America, said that independent clinics absolutely needed to be better funded, but that ultimately protecting the clinics depended on bigger changes.

I dont think they will be able to continue to operate at all if you dont shift the culture and politics, she said. The trajectory we are on will outlaw service.

Still, some worry that Planned Parenthood and other national groups have overly prioritized politics and power instead of patients and providers. Though Planned Parenthood is perhaps best known as the nations largest abortion provider, it provides a range of health services across more than 600 centers across the country, including contraception; testing for sexually transmitted infections; and hormone therapy for transgender patients.

The tension between Planned Parenthoods political goals and its mission as a health provider was one of the main reasons Dr. Wen, with a background as a physician, had such a stormy tenure as president.

Pamela Merritt, who co-founded a reproductive rights group called Reproaction in 2015, compared Planned Parenthoods legal priorities to a lobbyist for a commercial enterprise like McDonalds, focused on protecting its own business needs. Activists refer to the organization and its outsize influence, she said, as the big pink elephant in the room.

The movement needs independent providers that provide most abortions to be loud and out front, said Ms. Merritt, who described herself as an unapologetic lefty.

For many of those independent providers, the problem extends well beyond politics.

In Alabama, Ms. Grays biggest challenges are practical. Drug prices for medical abortions are high, she cant find a physician to replace her aging medical director, and an electrician recently refused services because he opposed abortion, she said.

Read more:
How a Divided Left Is Losing the Battle on Abortion - The New York Times

Recommendation and review posted by Bethany Smith

This press release was orginally distributed by ReleaseWire

Salt Lake City, UT -- (ReleaseWire) -- 12/01/2019 -- While Intermittent fasting may sound like another dieting craze, the practice of routinely not eating and drinking for short periods of time has shown again to lead to potentially better health outcomes.

In a new study by researchers at the Intermountain Healthcare Heart Institute in Salt Lake City, researchers have found that cardiac catheterization patients who practiced regular intermittent fasting lived longer than patients who don't. In addition, the study found that patients who practice intermittent fasting are less likely to be diagnosed with heart failure.

"It's another example of how we're finding that regularly fasting can lead to better health outcomes and longer lives," said Benjamin Horne, PhD, principal investigator of the study and director of cardiovascular and genetic epidemiology at the Intermountain Healthcare Heart Institute.

Findings from the study will be presented at the 2019 American Heart Association Scientific Sessions in Philadelphia on Saturday, November 16, 2019.

In the study, researchers asked 2,001 Intermountain patients undergoing cardiac catheterization from 2013 to 2015 a series of lifestyle questions, including whether or not they practiced routine intermittent fasting. Researchers then followed up with those patients 4.5 years later and found that routine fasters had greater survival rate than those who did not.

Because people who fast routinely also are known to engage in other healthy behaviors, the study also evaluated other parameters including demographics, socioeconomic factors, cardiac risk factors, comorbid diagnoses, medications and treatments, and other lifestyle behaviors like smoking and alcohol consumption.

Correcting statistically for these factors, long-term routine fasting remained a strong predictor of better survival and lower risk of heart failure, according to researchers.

The Intermountain Healthcare Heart Institute has the opportunity to closely study intermittent fasting because a large portion of its patients do it regularly: a significant segment of Utah's population belongs the Church of Jesus Christ of Latter-day Saints, whose members typically fast the first Sunday of the month by going without food or drink for two consecutive meals, and thus not eating for the period of about a day.

While the study does not show that fasting is the causal effect for better survival, these real-world outcomes in a large population do suggest that fasting may be having an effect and urge continued study of the behavior.

"While many rapid weight loss fasting diets exist today, the different purposes of fasting in those diets and in this study should not be confused with the act of fasting," said Dr. Horne. "All proposed biological mechanisms of health benefits from fasting arise from effects that occur during the fasting period or are consequences of fasting."

Dr. Horne has previously conducted studies about risk of diabetes and coronary artery disease in patients and found that rates are lower in patients who practice routine intermittent fasting. Those studies were published in 2008 and 2012 and suggested that the decades-long development of those chronic diseases may be ameliorated by long-term routine fasting.

Why long-term intermittent fasting leads to better health outcomes is still largely unknown, though Dr. Horne said it could be a host of factors. Fasting affects a person's levels of hemoglobin, red blood cell count, human growth hormone, and lowers sodium and bicarbonate levels, while also activating ketosis and autophagy all factors that lead to better heart health and specifically reduce risk of heart failure and coronary heart disease.

"With the lower heart failure risk that we found, which is consistent with prior mechanistic studies, this study suggests that routine fasting at a low frequency over two thirds of the lifespan is activating the same biological mechanisms that fasting diets are proposed to rapidly activate," Dr. Horne noted.

Researchers speculate that fasting routinely over a period of years and even decades conditions the body to activate the beneficial mechanisms of fasting after a shorter length of time than usual.

Typically, it takes about 12 hours of fasting for the effects to be activated, but long-term routine fasting may cause that time to be shortened so that each routine faster's daily evening/overnight fasting period between dinner and breakfast produces a small amount of daily benefit, they noted.

Further studies are on-going that will answer this question and other questions related to possible mechanisms of effects on development of chronic disease and survival. Additional research will also examine potential psychological effects of fasting and potential effects on appetite and perception of hunger.

Fasting is not for everyone. Researchers caution that pregnant and lactating women should not fast, as well as young children and frail older adults. People who have received an organ transplant, who have a suppressed immune system, who are experiencing acute or severe chronic infections, and those with eating disorders should also not fast.

Also, people diagnosed with chronic diseases especially those who take medications for diabetes, blood pressure, or heart disease should not fast unless under the close care and supervision of a physician because of the severe adverse effects that medications in combination with fasting can cause, including as hypoglycemia.

Other members of the Intermountain research team include: Ciera Bartholomew (BYU), Jeffrey L. Anderson, Heidi T. May, Kirk U. Knowlton, Tami L. Bair, Viet T. Le, Bruce W. Bailey (BYU), and Joseph B. Muhlestein.

This research study was funded by the Intermountain Research and Medical Foundation.

About Intermountain HealthcareIntermountain Healthcare is a not-for-profit system of 24 hospitals, 215 clinics, a Medical Group with 2,500 employed physicians and advanced practice clinicians, a health insurance company called SelectHealth, and other health services in Idaho, Utah, and Nevada. Intermountain is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes and sustainable costs. For more information, please see intermountainhealthcare.org.

For more information on this press release visit: http://www.releasewire.com/press-releases/intermountain-healthcare-study-shows-intermittent-fasting-increases-longevity-in-cardiac-catheterization-patients-1266497.htm

View post:
Intermountain Healthcare Study Shows Intermittent Fasting Increases Longevity in Cardiac Catheterization Patients - Press Release - Digital Journal

Recommendation and review posted by Bethany Smith

Dublin, Nov. 27, 2019 (GLOBE NEWSWIRE) -- The "Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the rapidly growing market of viral and non-viral vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies with in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe.

At present, 10+ genetically modified therapies have received approval / conditional approval in various regions of the world; these include (in the reverse chronological order of year of approval) Zynteglo (2019), Zolgensma (2019), Collategene (2019), LUXTURNA (2017), YESCARTA (2017), Kymriah (2017), INVOSSA (2017), Zalmoxis (2016), Strimvelis (2016), Imlygic (2015), Neovasculagen (2011), Rexin-G (2007), Oncorine (2005) and Gendicine (2003). In addition, over 500 therapy candidates are being investigated across different stages of development. The growing number of gene-based therapies, coupled to their rapid progression through the drug development process, has created significant opportunities for companies with expertise in vector manufacturing.

Presently, a number of industry (including both well-established companies and smaller R&D-focused initiatives), and non-industry players (academic institutes) claim to be capable of manufacturing different types of viral and non-viral vectors. In addition, there are several players offering novel technology solutions, which are capable of improving existing genetically modified therapy products and upgrading their affiliated manufacturing processes.

Considering prevalent and anticipated future trends, we believe that the vector and gene therapy manufacturing market is poised to grow steadily, driven by a robust pipeline of therapy candidates and technical advances aimed at mitigating existing challenges related to gene delivery vector and advanced therapy medicinal products.

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vehicles. The chapter also provides a brief description of the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market.

Chapter 4 provides a detailed overview of around 80 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, scale of production, type of viral vectors manufactured (AAV, adenoviral, lentiviral, retroviral and others), location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of production (fulfilling in-house requirements / for contract services).

Chapter 5 provides an overview of around 30 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 6 provides an overview of around 80 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, type of vectors manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others), applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 7 features detailed profiles of the US-based contract service providers / in-house manufacturers that possess commercial-scale capacities for the production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 8 features detailed profiles of EU based contract service providers / in-house manufacturers that possess commercial-scale capacities for the production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 9 features detailed profiles of Asia-Pacific based contract service provider(s) / in-house manufacturer(s) that possess commercial scale capacities for production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 10 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus-based vectors, Sendai virus-based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development/manufacturing of some of these novel vectors.

Chapter 11 features an elaborate analysis and discussion of the various collaborations and partnerships related to the manufacturing of vectors or gene therapies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers/acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2015. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of production and purpose of manufacturing (fulfilling in-house requirement/contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid DNA manufacturers based on the type of organization (industry / non-industry) and size of employee base. The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the locations of global vector manufacturing hubs across different continents.

Chapter 13 highlights our views on the various factors that may be taken into consideration while pricing viral vectors/plasmid DNA. It features discussions on different pricing models/approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.

Chapter 14 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analysed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 15 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations across different types of vectors (viral vectors, plasmid DNA, and both), scale of operation (clinical and commercial) and geographies (North America, EU, Asia-Pacific and the rest of the world).

Chapter 16 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 17 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.

Chapter 18 presents insights from the survey conducted on over 160 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 19 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 20 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Olivier Boisteau, (Co-Founder / President, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Colin Lee Novick (Managing Director, CJ Partners), Cedric Szpirer (Executive & Scientific Director, Delphi Genetics), Semyon Rubinchik (Scientific Director, ACGT), Alain Lamproye (President of Biopharma Business Unit, Novasep), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory), and Nicolas Grandchamp (R&D Leader, GEG Tech).

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Key Topics Covered

1. Preface2. Executive Summary3. Introduction4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Competitive Landscape5. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Competitive Landscape6. Vector and Gene Therapy Manufacturers (Non-Industry Players): Competitive Landscape7. Vector and Gene Therapy Manufacturers in North America8. Vector and Gene Therapy Manufacturers in Europe9. Vector and Gene Therapy Manufacturers in Asia-Pacific10. Emerging Vectors11. Recent Collaborations and Partnerships12. Key Insights13. Viral Vector and Plasmid DNA Cost Price Analysis14. Capacity Analysis15. Demand Analysis16. Market Sizing and Opportunity Analysis17. Key Drivers and Challenges18. Survey Analysis19. Concluding Remarks20. Executive Insights21. Appendix I: Tabulated Data22. Appendix II: List of Companies and Organizations

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/4m9jtt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Worldwide Markets for Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing, Forecast to 2030 - Robust Pipeline of Therapy Candidates and...

Recommendation and review posted by Bethany Smith

A research scientist at a laboratory of a pharmaceutical company in US. Reuters

The full scope of Novartis $500 million plan, revealed to Reuters in an interview with the companys gene therapy chief, has not been previously disclosed. It is second only to Pfizer, which has allocated $600 million to build its own gene therapy manufacturing plants, according to filings and interviews with industry executives.

Gene therapies aim to correct certain diseases by replacing the missing or mutated version of a gene found in a patients cells with healthy copies. With the potential to cure devastating illnesses in a single dose, drugmakers say they justify prices well above $1 million per patient.

But the treatments are also extremely complex to make, involving the cultivation of living material, and still pose a risk of serious side effects.

Drugmakers say building their own manufacturing plants is a response to rising costs and delays associated with relying on third-party contract manufacturers, which are also expanding to capitalise on demand. They say owning their own facilities helps safeguard proprietary production methods and more effectively address any concerns raised by the US Food and Drug Administration (FDA), which is keeping a close eye on manufacturing standards.

Theres so little capacity and capability at contract manufacturers for the novel gene therapy processes being developed by companies, said David Lennon, president of AveXis, Novartiss gene therapy division. We need internal manufacturing capabilities in the long term.

The approach is not without risks.

Bob Smith, senior vice president of Pfizers global gene therapy business, acknowledged drugmakers take a leap of faith when they make big capital investment outlays for treatments before they have been approved or, in some cases, even produced data demonstrating a benefit.

The rewards are potentially great, however.

Gene therapy is one of the hottest areas of drug research and, given the life-changing possibilities, the FDA is helping to speed treatments to market.

It has approved two so far, including Novartiss Zolgensma treatment for a rare muscular disorder priced at $2 million, and expects 40 new gene therapies to reach the US market by 2022.

There are currently several hundred under development by around 30 drugmakers for conditions from hemophilia to Duchenne muscular dystrophy and sickle cell anemia.

The proliferation of these treatments is pushing the limits of the industrys existing manufacturing capacity.

Developers of gene therapies that need to outsource manufacturing face wait times of about 18 months to get a production slot, company executives told Reuters.

They are also charged fees to reserve space that run into millions of dollars, more than double the cost of a few years ago, according to gene therapy developer RegenxBio.

As a result, companies including bluebird bio, PTC Therapeutics and Krystal Biotech are also investing in gene therapy manufacturing, according to a Reuters analysis of public filings and executive interviews.

They follow Biomarin Pharmaceutical, developer of a gene therapy for hemophilia, which constructed one of the industrys largest manufacturing facilities in 2017. The FDA is keeping a close eye on standards.

This comes amid the agencys disclosure in August that it is investigating alleged data manipulation by former executives at Novartis AveXis unit.

AveXis had switched its method for measuring Zolgensmas potency in animal studies. When results using the new method didnt meet expectations, the executives allegedly altered the data to cover it up, the FDA and Novartis have said.

One of the former executives, Brian Kaspar, denied wrongdoing in a statement to Reuters. Another, his brother Allan Kaspar, could not be reached for comment.

Novartis and the FDA say human clinical trials, which found Zolgensma effective in treating the most severe form of spinal muscular atrophy in infants, were not affected. Novartis also says its investments in gene therapy production started long before it became aware of the data manipulation allegations.

Reuters

Here is the original post:
Pfizer and Novartis lead pharma spending spree on gene therapy - Gulf Today

Recommendation and review posted by Bethany Smith

At an old Amgen facility tucked just beyond the Rockies. In a warehouse behind a Walmart supercenter in Durham, North Carolina. On a long-time Bristol Myers Squibb site outside Princeton. The tech has emerged, and now the arms race to physically build a generation of gene therapies has begun.

Novartis will spend $500 million scaling its gene therapy manufacturing efforts, Reuters reported today. Thatll put it nearly on par with Pfizer, who committed $600 million for its facilities even before any of its gene therapies have been approved. Together, 11 companies Reuters surveyed will spend $2 billion on gene therapy production.

Additionally, the Boston Globereported today that Vertex had completed its search for a gene therapy research and manufacturing campus in Boston, settling on a 256,000 square-foot center at the Raymond Flynn Marine Industrial Park.

Unlock this story instantly and join 66,600+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Go here to read the rest:
Korean biotech's shares soar for a 'best of ESMO' award it never received - Endpoints News

Recommendation and review posted by Bethany Smith

At an old Amgen facility tucked just beyond the Rockies. In a warehouse behind a Walmart supercenter in Durham, North Carolina. On a long-time Bristol Myers Squibb site outside Princeton. The tech has emerged, and now the arms race to physically build a generation of gene therapies has begun.

Novartis will spend $500 million scaling its gene therapy manufacturing efforts, Reuters reported today. Thatll put it nearly on par with Pfizer, who committed $600 million for its facilities even before any of its gene therapies have been approved. Together, 11 companies Reuters surveyed will spend $2 billion on gene therapy production.

Additionally, the Boston Globereported today that Vertex had completed its search for a gene therapy research and manufacturing campus in Boston, settling on a 256,000 square-foot center at the Raymond Flynn Marine Industrial Park.

Unlock this story instantly and join 66,600+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continue reading here:
Insider account of UCB's $2.1B deal to buy Ra Pharma spotlights a disciplined M&A strategy and $120M windfall for execs - Endpoints News

Recommendation and review posted by Bethany Smith

A new report titled Global Gene Therapy for Age-related Macular Degeneration Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2024 analyzes the leading players of the global market by studying their market share, partnerships, mergers, or acquisitions, recent developments, new product launches, and their target markets. The global Gene Therapy for Age-related Macular Degeneration market report not only studies strategies with aspects of competitors but also scrutinize their actions circling business preferences. It presents two distinct market forecasts, one from the perspective of the manufacturer, while other from that of the consumer for 2019 and forecast upto 2024.

The report contains a clear overview of the current Gene Therapy for Age-related Macular Degeneration market including the past and the projected future of market size with respect volume, technological advances, and economic elements in the industry. Also, a detailed analysis of the market share, demand, trends, revenue, and sales to track the development of the industry through the years has been performed in the report. The report highlights key use cases, key industry suppliers, adoption strategies, detailed case studies, trends, and other insights related to the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/320916/request-sample

Market Segments And Segmental Analysis:

The report has categorized the market size by vital players, varieties of types, application and distribution by top vital regions based on various factors such as market share, CAGR, market size, demand, and future growth potential. This will help players to focus on key growth areas of the global Gene Therapy for Age-related Macular Degeneration market. The regional analysis of the market has also been covered.

Top companies in the market: RetroSense Therapeutics, REGENXBIO, AGTC,

By the product type, the market is primarily split into: Subretinal, Intravitreal, Unspecified

By the end-users/application, this report covers the following segments: Monotherapy, Combination Therapy,

Major Geographical Regions:

The research study covers all big geographical, as well as, sub-regions throughout the world. The report focuses on market size, value, product sales and opportunities for growth in these regions. Each of these regions is analyzed on the basis of market findings across major countries in these regions for an understanding of the Gene Therapy for Age-related Macular Degeneration market. Leading countries covered in this report: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Key Features of Report:

ACCESS FULL REPORT: https://www.fiormarkets.com/report/global-gene-therapy-for-age-related-macular-degeneration-market-320916.html

A Quick Look At The Industry Trends And Opportunities

The report explains how different segments are contributing to the growth of the global Gene Therapy for Age-related Macular Degeneration market. Key trends related to the segments are comprehensively added in the report in order to help market players concentrate on high-growth areas of the market. The industry dynamics such as market advantages, opportunity, prospects, potential, and challenges are further highlighted in the report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

More here:
Global Gene Therapy for Age-related Macular Degeneration Market 2019 Development Status RetroSense Therapeutics, REGENXBIO, AGTC - Mach Tribune

Recommendation and review posted by Bethany Smith

Some patients who have not responded to traditional medicines are now experiencing remarkable recoveries thanks to next-generation immunotherapies.These therapies equip a patients own immune cells to recognize, target, and destroy cancer cells. To do this, the patients cells are collected, modified, and re-introduced into their body a complex procedure currently available to only a small number of people. With major innovations underway, this fast-moving area of science is set to expand the pool of patients who will respond to immunotherapies and other emerging medicines. But there is a bottleneck in the discovery pipeline. Manufacturing backlogs are slowing the production of cells that are essential to research, holding up the availability of new treatments headed for the clinic.

To address these challenges, a group of Massachusetts academic, healthcare, biotech, and biopharma industry leaders have come together to establish a new center.

The newcenter for advanced biological innovation and manufacturingwill explore and cultivate innovations in cell and gene therapy, advance biologic innovation and manufacturing, and accelerate developments in immunotherapy, cell therapies, gene editing, and other technologies that carry the promise of lasting impact on human health globally and boosting the local economy. By fostering collaboration and innovation, it holds the promise of speeding innovation and broadening the universe of patients that can be served by these emerging therapies.

Leaders from Harvard University, Massachusetts Institute of Technology (MIT), Fujifilm Diosynth Biotechnologies (FDB), GE Healthcare Life Sciences, Alexandria Real Estate Equities, Inc., will comprise the Board of Directors, while other contributing members include Beth Israel Deaconess Medical Center, Boston Childrens Hospital, Brigham and Womens Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, MilliporeSigma, and the Commonwealth of Massachusetts.

The $50 million center will be an independent non-profit organization located in the greater Boston area and will be named, along with incorporation, in the new year. The expectation is that this will be an independent, separate nonprofit corporation.

Home to a dense concentration of world-leading universities, hospitals, large pharmaceutical companies and small biotech firms, Massachusetts is at the forefront of biomedicine. These organizations are redefining traditional ideas about biomedicine and rapidly advancing discoveries from lab to clinic.

The overarching mission of the newly established consortium is to catalyze the development of transformative therapies by shortening the path between research and clinical application. The consortium will harness world-leading expertise to propel forward fast-emerging and promising science, the cost and risks of which are daunting for any single institution to tackle alone. By housing institutions with strengths in each link in the chain of innovation within one facility, the partners believe new innovations in both science and manufacturing will speed the introduction of new medicines to patients.

The ability of scientists to modify cells for therapeutic application, and to alter disease-causing genes, has ushered in a new era in biomedicine. Some of these potential therapies are entering clinical trials, others will soon be in the clinic, and still more are in early stages of investigation. There is strong motivation and acute need to translate these emergent approaches to clinical use. More than 60,000 patients globally are currently participating in clinical trials for new cell and gene therapies, including gene editing.

Currently, major obstacles and bottlenecks to getting new treatments into the clinic include production specifically, the pressure placed on highly skilled contract manufacturers to deliver customized cells and viral vectors of high quality and regulatory compliance to labs throughout the region. Because of the backlog, scientists may need to wait as long as 18 months for essential products they need to carry out research.

The center will offer three critical services to the Massachusetts life science ecosystem.

It will provide preferred access to a new manufacturing facility at favorable pricing, reducing the wait and cost for researchers at universities, hospitals and start-ups. The facility offers pharma-grade good manufacturing practices (GMP) manufacturing capacity in approximately eight cleanrooms for the production of cell and viral vector products and other related raw materials that may be used for phase 1 or phase 2 clinical trials.

The facility will have a shared innovation space where scientists from universities, hospitals, and industry can work side-by-side with dedicated, experienced, professional staff. This will be a unique opportunity to refine new methods rapidly, readying them for first-in-patient clinical trials. With access to manufacturing within the same space, the center will cultivate a community of experts across sectors who share a goal of serving patients, and who are dedicated to innovating collectively in both manufacturing processes and drug development.

The center will provide a platform for workforce development and training in a rapidly growing field, where there is a critical need for people with specialized skills.

The modular design of the new facility will make it easier for users to adapt quickly to changes in technology. Such flexibility will remove barriers to accessing promising innovations that emerge from improved methods involving gene manipulation, gene editing, oligonucleotides, peptides, and new methods and discoveries as they arise.

While there are many commercial contract manufacturing organizations, shared lab spaces, and even small manufacturing spaces at universities and hospitals in the U.S., this is a first-of-its-kind facility in three respects. First, for its intention to produce both cell and viral vector products within a single physical space. Second, for its unique partnerships between industry, academia, and leading area hospitals. Finally, for its partners aspirations to provide services to researchers and start-ups that will advance this new area of medicine through collaboration.

This powerful collaboration embodies the deep and broad world-class expertise in multiple disciplines that exists across this region, said Harvard President Larry Bacow. We are privileged to be part of this collaborative initiative. It will advance scientific discovery, reaffirm the regions global leadership in the life sciences, and bring forward life-saving and life-changing therapies that will make a difference for people around the world.

The broad question that we were trying to address was, How can we best position our region to be preeminent in the life sciences in the decades to come?said Alan M. Garber, Harvards Provost, who helped conceive of the project more than two years ago and has shepherded it since then.We have a vibrant life sciences community, with some of the worlds greatest hospitals, universities, and life sciences companies of all kinds. We also have a strong financial sector that helps to spawn and support new companies. So the elements for rapid progress in the life sciences particularly in the application of the life sciences to human health are all here. But with such a rapid pace of innovation, its easy to fall behind. We wanted to make sure that would not happen here.

MIT researchers are developing innovative approaches to cell and gene therapy, designing new concepts for such biopharmaceutical medicines as well as new processes to manufacture these products and qualify them for clinical use, said MIT Provost Martin A. Schmidt. A shared facility to de-risk this innovation, including production, will facilitate even stronger collaborations among local universities, hospitals, and companies and ultimately, such a facility can help speed impact and access for patients. MIT appreciates Harvards lead in convening exploration of this opportunity for the Commonwealth.

Richard McCullough, Harvards vice provost for research and professor of materials science and engineering, who helped lead the project, said, the power of facilitys partners will accelerate therapeutic discoveries and have the ability to advance biologics from the lab to the bedside.

Its an exciting time for the life sciences industry with cell and gene therapies in position to revolutionize the global healthcare system. While these therapies are promising, challenges in manufacturing, access and cost must be addressed so they can reach their full potential. Initiatives such as the center are important because they bring together key life sciences stakeholders together to share their capabilities, knowledge and expertise to collaborate and accelerate innovation, said Emmanuel Ligner, CEO and President of GE Healthcare Life Sciences.

We are very proud to be part of this unparalleled consortium to create an innovative and collaborative centerinvolving advanced technologies as well asnext-generation manufacturing. The highly respected partner institutions have the scientific talent andtheengineering capabilities to deliver truly novel therapies to patients sufferingtodayfrom serious and life-threatening diseases and also to design the next-generation processes that will accelerate the translation of tomorrowscost-effective, lifesaving medicines from bench to bedside, said Joel S. Marcus, executive chairman and founder, Alexandria RealEstateEquities, Inc. and Alexandria Venture Investments.

We are excited to be a founding member of this consortia.Partnering to get medicines to patients is what we are all about. The opportunity to do this in collaboration with everyone that has come together to make this a reality is something that really meets our core purpose to deliver tomorrows medicines as a partner for life, said Martin Meeson, President & COO, FUJFILM Diosynth Biotechnologies USA.

Massachusetts new center for advanced biological innovation and manufacturing will focus first on emergent areas such as cell therapies and gene therapies, and other advanced therapy medicinal products. Cell therapies that help a patients own immune system target cancer cells have been remarkably successful. One example is CART cell therapy, in which a patients own T cells are modified to identify and attack cancer cells in the blood more easily. But immunotherapy is not restricted to treating cancers. Scientists are finding new ways to harness the immune system to treat a broad spectrum of diseases, including type 1 diabetes and many others. Cell therapies more broadly harnessing unique properties of adult stem cells, for example are under wide consideration for regenerative medicine, including joint tissue repair and neurodegeneration.

Gene therapies offer new hope to patients, often children, who suffer from debilitating inherited diseases. They involve introducing, removing, or changing a targeted gene within a patients cells. The goal is to make the patients cells produce disease-fighting proteins, or to stop them from producing disease-causing versions of a protein. Gene-editing research is progressing very rapidly, but there is a marked shortage of capability for manufacturing the gene delivery vectors.

Hospitals need to be able to create customized therapeutics for their patients, but most do not have manufacturing facilities on-site. Beyond the constraint of limited facilities to produce potential new treatments, much technological innovation is required to produce these medicines more efficiently in terms of time, labor, and cost and in accordance with regulatory guidance. The new center would be equipped to handle some of this work for technology innovation and early stage clinical trial-scale production, which would directly help bring promising solutions to patients sooner.

Scientific breakthroughs in cellular, immune and gene therapies from just the past few years are now saving lives and represent a truly revolutionary time in medicine, said Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute. By bringing together the talent that exists only in the Massachusetts life sciences ecosystem and fostering collaboration, this new manufacturing center will help to extend the benefit of these technologies to more patients and accelerate discoveries to effectively treat more diseases.

We need more manufacturing capability in order to translate our work, especially in the stem cell field, said Leonard Zon, MD, director of the Stem Cell Research Program at Boston Childrens Hospital. For academic investigators who want to see their basic science advance into the clinic space, its important to have a manufacturing facility collaborate on protocols. Researchers can then exchange information directly with the facility, optimizing protocols and working smarter.

This collaboration represents an exciting opportunity to harness the collective efforts of leading academic, industrial and clinical institutions to further explore exciting new technologies and therapies that are inspiring scientists and offering new hope to our patients, says Peter L. Slavin, MD, MGH president. New scientific fields like regenerative medicine, gene editing and immunotherapy are unlocking clues to understanding disease which can lead to better treatments and ultimately, richer, more healthy lives for our patients and their families.

Our mission at Beth Israel Deaconess Medical Center is to provide extraordinary care supported by world-class research and education, said Peter J. Healy, president of Beth Israel Deaconess Medical Center. We are happy to be a founding member of this innovative consortium, which will allow us to work collaboratively across the diverse health care ecosystem. Together, we will propel the fields of cell therapy, gene therapy and gene editing forward with the shared goal of transforming how we care for patients right here in Boston and around the world.

Boston is an epicenter of biomedical research and innovation, said Brigham Health president Elizabeth G. Nabel, MD. In furthering the Brighams commitment to advancing development and delivery of cell and gene therapies, this unique collaboration is an opportunity to accelerate the pace and broaden the manufacturing capacity for therapies that have the potential to significantly improve patient outcomes.

Never before have we had so many breakthroughs available in the clinic. However, it can take up to 30 days, needle to needle, to deliver a CAR-T therapy to a patient, and that does not take into account any of the bottlenecks in the supply chain that could occur along the way. It is our collective responsibility to eliminate any barriers to making these life-saving medicines accessible to patients everywhere, said Udit Batra, CEO, MilliporeSigma.

The Commonwealths life sciences ecosystem is thriving because of the strength of the academic, research and industry partners that call Massachusetts home, and their commitment to collaboration, said Secretary of Housing and Economic Development Mike Kennealy. Combining a manufacturing facility, co-working labs, and workforce development and training in this first-in-the-nation center will boost the regional economy, create jobs and accelerate the delivery of next-generation therapies.

Read more here:
Harvard, MIT, teaching hospitals, industry partners pool resources to create a central facility for developing regenerative therapies - India...

Recommendation and review posted by Bethany Smith

Hes done it - Stephen Armstrong has scooped a prestigious award for his huge fund raising efforts as his son fought a rare blood disorder.

The doting dad took home the award for Individual Fundraiser of the Year at the Anthony Nolan Supporter Awards 2019 ceremony held at the Tower of London.

The top awards were back for their seventh year to recognise the outstanding achievements of the volunteers, fundraisers and campaigners who help the pioneering blood cancer charity save lives.

And the award is in recognition of Stephens incredible fundraising efforts - leading a group of 19 friends and family in a series of physical challenges, all while his son Jacob was undergoing treatment.

When Jacob was diagnosed in 2017 at two-years-old, Stephen set out to find a matching stem cell donor, as well as raise awareness of the need for more people on the register.

From here Jacobs Journey was born, and through a series of challenges including the Great North Run, the Great North Bike Ride and climbing Ben Nevis, Stephen has helped raise over 20,000 for the charity.

Jacob is now four-years-old and his family have been told he does not need a transplant, but Stephen and his family want to continue raising awareness for others who arent so lucky.

When Jacob was diagnosed, we were stunned by how few people were on the stem cell donor register. I couldnt believe how a stranger in the street could potentially save our little boys life, said Stephen, 33, of Wallsend,North Tyneside.

On winning the award, Stephen said: I feel very proud- I really didnt expect it. You dont do it for recognition, but to get more people to join the register.

Stephen and mum Kirsty, 28, received the news in December 2017 that Jacob was suffering from bone marrow failure, which affects between 30 and 40 children each year.

They first became concerned about his health when they went abroad to get married and noticed he was getting bruised easily. The marks would take weeks to disappear, so when the couple returned to the UK they decided to take Jacob to the doctor for a check up.

After tests he was then diagnosed and was treated at the Great North Childrens Hospital in Newcastle, where he received two blood transfusions.

Stephen, who has raised a further 8,000 for other smaller charities, added: When we were told Jacob did not need the transplant it was the best news in the world, a total relief. He still needs check ups every three months and his consultants is keeping an eye on him. There are so few people on the stem cell donor register so I just wanted to create a ripple effect with awareness and get more people on it.

Henny Braund, Chief Executive at Anthony Nolan, said: Stephen is a hugely deserving winner of this award; his incredible support and passion for our work is a fantastic example of our charity, which is built on making lifesaving connections. It was lovely to meet Stephen and I continue to find myself inspired and humbled by the dedication and strength of supporters like him.

By raising vital funds and much needed awareness, we are curing blood cancer together. We can give families hope, and give more people a future. But without supporters like Stephen, lives cant be saved. Without him, there is no cure.

Anthony Nolan is the charity that finds matching stem cell donors for people with blood cancer and blood disorders and gives them a second chance at life. It also carries out ground-breaking research to save more lives and provide information and support to patients after a stem cell transplant, through its clinical nurse specialists and psychologists, who help guide patients through their recovery.

To see the full shortlist, and find out more about the charity visit the website here.

See more here:
Wallsend dad who called on the public for stem cells for his son scoops top Anthony Nolan Award - Chronicle Live

Recommendation and review posted by Bethany Smith

MAGICAL Nature is Rebecca Bennett's first exhibition in four years following her stem cell transplant.

Running throughout December at Rydal Hall Old School Room Teashop at Ambleside, the exhibition features various media from acrylics and watercolours to photography.

Rebecca loves capturing the magic of colour and pattern within nature in her artwork. She grew up surrounded by the beautiful fells and lakes of Cumbria. Coming from an artistic family, painting and drawing from an early age was natural.

From photographs of lakes seen through the prism of a crystal ball to an enigmatic acrylic painting of a grey heron, Magical Nature includes striking images of the wildlife and countryside of Rebeccas native Lake District.

With a BA(hons) degree in Contemporary Applied Arts from Cumbria Institute of the Arts, Rebecca furthered her art practice and skills to create porcelain ceramic pieces and textile mixed media artworks.

Following university Rebecca completed a variety of successful art projects and workshops alongside her exhibitions. These included art workshops with young people at the Coniston Water Festival and Blencathra Field Studies Centre.

In 2015 Rebecca had a stem cell transplant at London's Kings College Hospital. An unrelated donor provided the stem cells to treat failing bone marrow caused by rare Gata2 deficiency and Myelodysplastic Syndrome. Painting and photography have, she says, been a great therapy throughout her transplant journey.

"When you feel up to it having something to immerse yourself in such as art and photography can be a fantastic way to help you forget about your pain and problems. For those moments, you are focused on what you are creating and can escape for a little while."

Alongside exhibiting her work for the first time since being diagnosed with her illnesses, Rebecca hopes to raise awareness of MDS and blood disorders. Donations to the charity MDS UK patient support will be made from sales of Rebeccas greeting cards and prints during the exhibition.

Originally posted here:
Artist's first exhibition following stem cell transplant - The Westmorland Gazette

Recommendation and review posted by Bethany Smith

By Blaine Curcio

The Asia Pacific Satellite Communications Council (APSCC) is, among other things, arguably the premier satellite communications (satcom) member organization in Asia-Pacific. From its headquarters in Seoul, the APSCC publishes a quarterly newsletter on regional industry ongoings, provides assistance on issues such as spectrum coordination, and, most notably for the purposes of this article, puts together the APSCC Conference in October/November of every year. I often tell people that ConnecTechAsia (formerly Communicasia) in Singapore is a bit like the Asian equivalent to the SATELLITE conference in Washington DC every yearthat is, a stadium-sized convention center with thousands of people clamoring to see massive booths. In contrast, APSCC is a bit more like the Asian version of the Euroconsult World Satellite Business Weekit is smaller, much more intimate (always in a very comfortable hotel), and the attendees, while vastly fewer in number, are higher in pay-grade. It is, in short, a leadership summit of the APAC satellite (and increasingly, space) industry.

In addition to all of the above, the APSCC is also an organization in transition, with the transition involving two major prongs1) broaden the scope from satcom to space, more generally, and 2) create a more international, inclusive organization. This transition is an exciting one, and was fully on display at this years APSCC Conference, which was held from 19-21 November at the Intercontinental Bangkok. Having represented Euroconsult on the conference organizing committee over the preceding ~10 months, and having sat front row center (just next to the omnipresent Peter de Seldingthey should really give him his own microphone), I was delighted to see young people, companies I had never heard of, and an increasing representation of women in a region that is oftentimes rather male-dominated. Having spent the better part of a week surrounded by some of the industrys brightest minds, some key trends emerged surrounding the Asian space industry.

The Young Shall Inherit the Earth

One of the most striking elements of the APSCC conference was the number of young people. The biggest example of this was the Youth Development Workshop on the conferences 3rd day, which brings in university students from the host country for a workshop on satellite and space. However, more impressive were the number of startups that were actively participating in the conference, being led by founders born in the 1980s or 1990s.

Day 3 of the conference, for instance, started with a keynote from Tim Ellis, CEO of Relativity Space, a company aiming to 3D-print rockets. The company has raised around US$200 million, with a CEO that is, at the oldest, 29. If Mr. Elliss goal were to win the youngest CEO of a rocket company at this conference award, however, he would need a time machine to bring him back about 6 years, because Simon Gwozdz, the CEO of Equatorial Space Industries (a Singaporean launch startup that presented on Day 3), is roughly 23 years old, having graduated from university in 2019. Given that no launch companies at the conference had founders under age 23, he also won said youngest founder award, which was given out after the conference (not really).

Separate to the plethora of rocket companies founded people born in the 1990s, the conference featured a New Space Pitch Competition for the first time, which brought in a number of New Space companies to pitch judges and the audience on their businesses. The startups were, likewise, full of young people. Having never heard of most of these startups before, I was impressed and to a certain extent blown away by the innovative ideas and energy brought onto the stage, including companies focused on in-orbit life extension, small launch, and beam-hopping technology.

A different type of youth also showed up in spades during the conference, with one of Asias youngest (read: newest) countries, and fairly recent New Space entrant Singapore being strongly represented at the New Space Pitch Competition, as well as at the conference more generally, with an increasing number of space companies calling the Little Red Dot home, or at a minimum, APAC HQ. Following the conference, I was kindly invited to a Singapore New Space WhatsApp group with over 100 members, an anecdotal indication of the growing space community in the Lion City.

In Satcom, the Times They are AChangin

The satellite industry is changing rapidly, and this was clear from the 3-day event. This change is occurring in several ways. First, the industry is transitioning from being a TV broadcaster in the sky, to being a telco in the sky.

Pasifik Satelit Nusantara (PSN), an Indonesian satellite operator, reported that today, the company connects 5,000 rural villages in Indonesia to the Internet via satellite, with these 5,000 villages including 5 million people. The companys ambitious target is to cover 20,000 villages, and 20 million people, by the end of 2020. This has been enabled in part by another change, and one that is particularly noteworthy in Southeast Asiathe fall of C-band, and the rise of Ka-band. For years, naysayers held that the climate in Southeast Asia was far too rainy for Ka-band to be feasible, while holding that C-band, with its higher reliability in the face of rain, would remain the go-to frequency. In the case of PSN, this is not the case, with the companys CEO, industry veteran Adi Adiwoso, making it patently clear that the only way to serve the masses with internet connectivity would be to use Ka-band, even in rainy Indonesia, because frankly speaking, there just isnt enough spectrum in C-band or Ku-band to enable the bandwidth economics required. A representative from KTSAT echoed the bearishness on C-band, noting that in South Korea, there are already 4 million 5G subscribers, and that very soon, the spectrum allocated to 5G will become saturated, requiring more spectrum to be re-allocated.

In addition to moving into new frequency bands and new verticals, the satcom industry is achangin in even more out there ways. During a lunch sponsored by Sky Perfect JSAT, the satellite operator of Japan, we were treated to a short video, which showed JSATs current ongoings and future ambitions. The more interesting components of this involved a partnership with Japanese EO company Axelspace, plans to provide communications services to human activity in outer space, and other business models that are far outside of the selling megahertz to video broadcasters business model that has for so long paid our bills and dominated industry rhetoric. Separate to this, satellite operators such as KTSAT of Korea spoke about integrating with 5G networks, while Measat sent a representative from their ConnectME consumer broadband business to be their Young Talent Award nominee.

Finally, the Satellite Executive of the Year award, presented to the most outstanding satcom industry executive in the region, went to Christian Patouraux of Kacific, a startup satellite operator aiming to offer low-cost, Ka-band high-throughput capacity in APAC, nearly exclusively for data connectivity as opposed to the more traditional video broadcast verticals. If there was any further need for an indication that the satcom industry is changing, and that those leading the change are being recognized for their work, this was it, with the companys satellite to launch next month to a strong pre-existing book of business, and tens of thousands (or more) unserved or underserved waiting customers.

The Rapidly Evolving Space Industry

While the times are clearly achangin in satcom, the broader space industry is also experiencing a rapid change, and APSCC was a showcase for such change. Completely new business models are emerging. On one panel, there was discussion of a company that wanted to offer connecting flights to space (Momentus, a California-based company that aims to offer rides from LEO to other orbits), while another strived to be a space garbage man (AstroScale, a Japanese company that is focusing on cleaning up orbital debris). 3D printing is starting to play a bigger role, with Relativity Space, the aforementioned rocket company, noting that 95% of the companys rocket parts are made using 3D printers. The company claims a launch price of $10 million for a 1,250kg payload to LEO, working out to US$8,000 per kg, a competitive price to be sure.

Another more macro change within the industry that was perceptible during the conference was the increasing number of Chinese companies, both state-owned giants and private startups. For the first time, China Satcom participated in the Asia satellite operator panel, while LandSpace and Ultimate Blue Nebula (UBN), a rocket company and consulting firm, respectively, participated in a China space industry panel. Companies such as Starwin, an antenna manufacturer from Chengdu, also made an appearance. Moving forward, with over 100 private space startups in China, and with a large number of them looking internationally as well as domestically, we will likely see an increase in the number of Chinese companies represented at APSCC, and other events in the region.

Conclusions

During the conference, several long-time attendees approached me saying that it had been the best APSCC ever. A dynamic APAC satcom industry, a slew of youthful startups coming from all across the region (with many from Singapore), and a variety of more established New Space companies entering the fray made for a truly out-of-this-world conference. In the coming years, we are likely to see an even more diverse audience, with even more new business models, contributing to a conference that is rapidly becoming the premier space event in APAC.

*Disclaimerhaving attended APSCC on two other occasions, this year was the first in which I was also a member of the conference organizing committee. That being the case, my analysis may at times border on subjective.

Blaine Curcio is the founder and owner ofOrbital Gateway Consulting, a boutique market research and consulting firm focusing onemerging commercial opportunities in space and satellite industry, as well as the Chinesespace/satcom market. Blaine is also a senioraffiliate consultant for Euroconsult, and is based in Hong Kong. Blaine can be contacted at: [emailprotected]

Go here to read the rest:
#SpaceWatchGL Column: Reflections on the 2019 APSCC Conference - Putting on a Show in the Land of Smiles - SpaceWatch.Global

Recommendation and review posted by Bethany Smith

A Derbyshire mum hanged herself after finding out she had an incurable brain tumour, an inquest heard.

Tracy Wardle was described as having everything to live for, including a young daughter, before receiving the devastating diagnosis.

Mrs Wardle, 36, from Langley Mill, was found by her partner on Wednesday, September 12, 2018.

The inquest heard that, just hours before her death, Mrs Wardle had woken up her partner, wanting to be comforted because she was in pain.

Mrs Wardle, a nursery nurse, had been told by doctors that any treatment she had would only control the tumour.

A woman at the inquest said she and Mrs Wardle had been best friends for over 20 years.

She said: She had a brain tumour and we went through all that with her.

She was in a lot of pain. She had enough.

Her daughter was her biggest priority in life.

The inquest heard that Mrs Wardle, who was born in Salford, was estranged from her husband but they remained close friends.

Assistant coroner Louise Pinder said Mrs Wardle was awaiting results from a scan when she died.

She said: She was found hanging on the stairs by her partner.

She started to have seizures that led to the diagnosis.

Oncology were finding it difficult to engage with her. She was in denial about how serious it was.

The best that could be offered to her was life extension, not a cure.

A spokesperson at Derbyshire police said they were asked to attend a house in Langley Mill at 1pm on September 12, 2018.

She said paramedics from East Midlands Ambulance Service were already at the scene and told officers that Mrs Wardle had died.

The officer said her partner of one year had woken up after midday, realised Mrs Wardle wasnt in bed and had then seen Tracy at the top of the stairs.

She said: He realised that she appeared to be deceased. He got a knife from the kitchen and cut the scarf and placed her body at the top of the stairs. He was in a lot of shock.

He then rang emergency services.

The officer added: Her partner said in the night she asked him to hug her at 2am. She had woken him up to say my head is hurting, can you comfort me.

I believe shes been in pain and its been a quick act. It was a snap decision.

She said Mrs Wardle was close to her young daughter but due to her physical health she couldnt have full care.

The pathologist said a post mortem examination had been carried out which showed there were no signs of an overdose.

Mrs Wardles GP at Brooklyn Medical Practice, in Langley Mill, said she had been registered to the surgery in May 2018 after suffering from a seizure.

He said in April 2018 she had surgery on the grade four tumour, one whose cells grow rapidly and spread faster than tumours with a lower grade.

Later, she was taken to A&E by a friend after she reported feeling strange and hearing voices.

He said Mrs Wardle accepted chemotherapy and radiotherapy but all treatment was aimed towards controlling things.

The inquest heard that, by August, Mrs Wardle had finished her radiotherapy treatment.

She was seen by her GP and a Macmillan representative in August who were concerned about her as she had not taken her medication.

Her friend added: We were all shocked. She had been planning things for the future. The brain tumour was why it all happened.

She had everything to live for, she just got a house and started a new life with her partner. She had a daughter.

When she was diagnosed it all fell apart.

The coroner agreed with the pathologists findings that Mrs Wardle died due to asphyxia after being found hanging by a ligature.

He also referenced her depression and that she was being treated for a brain tumour.

Mrs Pinder said: I conclude that Tracey took her own life.

She was very well supported by her friends and family.

In the face of this catastrophic diagnosis, it seems something overwhelmed her that night and as a result of that she carried out this act.

Shes a huge loss to you.

Samaritans (116 123) operates a 24-hour service available every day of the year. If you prefer to write down how youre feeling, or if youre worried about being overheard on the phone, you can email Samaritans at jo@samaritans.org

Read this article:
Beloved Derbyshire nursery nurse took her own life over incurable brain tumour - Derbyshire Live

Recommendation and review posted by Bethany Smith

Ample Market Research has come up with a newly published report on S adenosylmethionine (SAM e) market study with 100+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on S adenosylmethionine (SAM e). S adenosylmethionine (SAM e) research allows you to get different methods for maximizing your profit. The research study provides estimates for S adenosylmethionine (SAM e) Forecast till 2025*. The top players cover Doctors Best, Metabolic Maintenanc, Now Foods, NutraLife, California Gold Nutrition, Jarrow Formulas, Source Naturals, Life Extension Etc., which are playing important roles in the S adenosylmethionine (SAM e) market.

Click to get S adenosylmethionine (SAM e) Market Research Sample PDF Copy Here: https://www.amplemarketreports.com/sample-request/global-and-regional-s-adenosylmethionine-industry-1214518.html

The S-adenosylmethionine (SAM-e) market size will grow from XX Million USD in 2018 to XX Million USD by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2019 to 2024.

S adenosylmethionine (SAM e) Research for a Leading company is an intelligent process of gathering and analyzing the numerical data related to services and products. This Research Give idea to aims at your targeted customers understanding, needs and wants. Also, reveals how effectively a company can meet their requirements. The market research collects data about the customers, marketing strategy, competitors. The S adenosylmethionine (SAM e) Manufacturing industry is becoming increasingly dynamic and innovative, with more number of private players entering the industry.

Important Features that are under offering & key highlights of the report:

1) Who are the Leading Key Company in S adenosylmethionine (SAM e) market space?

Following are list of players that are currently profiled in the report Doctors Best, Metabolic Maintenanc, Now Foods, NutraLife, California Gold Nutrition, Jarrow Formulas, Source Naturals, Life Extension

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

2) What will the market size be in 2025 and what will the growth rate be?

In 2019, the S adenosylmethionine (SAM e) market size was xx million USD and it is expected to reach USD xx million by the end of 2025, with a CAGR of xx% during 2019-2025.

3) What are the Market Applications & Types:

The study is segmented by following Product Type: Chemical Synthesis, Fermentation, Enzymatic Conversion

Major applications/end-users industry are: Scientific Research, Clinical Treatment, Others

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2018 currency rates.

To comprehend S adenosylmethionine (SAM e) market dynamics in the world mainly, the worldwide S adenosylmethionine (SAM e) market is analyzed across major regions.We also provides customized specific regional and country-level reports for the following areas.

Enquire for customization in Report https://www.amplemarketreports.com/enquiry-before-buy/global-and-regional-s-adenosylmethionine-industry-1214518.html

Competitive Analysis:

The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as Doctors Best, Metabolic Maintenanc, Now Foods, NutraLife, California Gold Nutrition, Jarrow Formulas, Source Naturals, Life Extension includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.

Research Parameter/ Research Methodology

Primary Research:

The primary sources involves the industry experts from the S adenosylmethionine (SAM e) industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the S adenosylmethionine (SAM e) in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Buy Full (Single User License) Copy of S adenosylmethionine (SAM e) Report 2019 at https://www.amplemarketreports.com/buy-report.html?report=1214518&format=1

This report on the S adenosylmethionine (SAM e) market is prepared on the basis of the following years or time period:

Forecast Period: 2019-2025

Estimated Year: 2019

Base Year: 2018

Historical Period: 2014-2019

Key Stakeholders in S adenosylmethionine (SAM e) Market:

S adenosylmethionine (SAM e) Manufacturers

S adenosylmethionine (SAM e) Distributors/Traders/Wholesalers

S adenosylmethionine (SAM e) Sub component Manufacturers

Industry Association

Downstream Vendors

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in S adenosylmethionine (SAM e) Market Research Report at https://www.amplemarketreports.com/report/global-and-regional-s-adenosylmethionine-industry-1214518.html

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: Jamuna Tower, 501, MIDC Road, Miragaon, Mira Road East, Mumbai, Maharashtra 401107

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

Website: http://www.amplemarketreports.com

View original post here:
S-adenosylmethionine Market 2019 Trends, Size, Share, Growth Insight, Competitive Analysis, Segments Overview, Regional, And Global Industry Forecast...

Recommendation and review posted by Bethany Smith